- Consumer Products
- Latest 15.45
- Currency US$
- Change 0.13
- Percent Change 0.849 %
- Volume 5,595
- Fri Mar 7, 2014 09:36 AM EST NASDAQ data delayed 15 minutes.
12 months ended Sep 30, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||Mar 5||$1.29||May 6||--|
12 months ended Mar 07, 2014.
A look at major corporate events and financial announcements that are coming up.
About the Company
OSIRIS THERAPEUTICS, INC. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products.